ReviewThe Journal of antimicrobial chemotherapy2008
Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?
Review in The Journal of antimicrobial chemotherapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Comparative effectiveness of anti-viral drugs with dual activity for treating hepatitis B and HIV co-infected patients: a network meta-analysis.BMC infectious diseases · 2018Article
- Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance.World journal of gastroenterology · 2016Review
- Development and Validation of Two Screening Assays for the Hepatitis C Virus NS3 Q80K Polymorphism Associated with Reduced Response to Combination Treatment Regimens Containing Simeprevir.Journal of clinical microbiology · 2015Article
- Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection.PLoS computational biology · 2015Article
- In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor.Antimicrobial agents and chemotherapy · 2015Article
- Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?Hepatic medicine : evidence and research · 2015Review
- Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort.Journal of acquired immune deficiency syndromes (1999) · 2014Article
- A new stochastic model for subgenomic hepatitis C virus replication considers drug resistant mutants.PloS one · 2014Article
- Update on HIV/HCV coinfection.Current HIV/AIDS reports · 2013Review
- Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment.Journal of virology · 2013Article
- Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatment.Antimicrobial agents and chemotherapy · 2013Article
- Highlights from the 2012 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the search of an HIV cure.AIDS research and therapy · 2012Article
- Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor.Bulletin of mathematical biology · 2012Article
- Convergence and coevolution of hepatitis B virus drug resistance.Nature communications · 2012Article
- Hepatitis: Treatment failure in chronic hepatitis B.Nature reviews. Gastroenterology & hepatology · 2011Article
- Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.Viruses · 2010Article
- Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing.Journal of virology · 2010Article
- A novel small molecule inhibitor of hepatitis C virus entry.PLoS pathogens · 2010Article
- Rapid emergence of protease inhibitor resistance in hepatitis C virus.Science translational medicine · 2010Article
- Ultrasensitive genotypic detection of antiviral resistance in hepatitis B virus clinical isolates.Antimicrobial agents and chemotherapy · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The arrival of new antiviral drugs to treat chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections has given rise to great expectations along with concerns regarding the selection of drug-resistant variants. Many lessons learnt from HIV therapeutics can be helpful for designing adequate treatment strategies against viral hepatitis, the avoidance of sequential weak monotherapies being one of them. Although HIV, HBV and HCV share many biological features, including very rapid viral dynamics, distinctive characteristics explain why the speed of selection of drug resistance differs substantially between these viruses, being faster for HCV than for HIV and slower for HBV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.